-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师的观点总结如下：MUR公布第一季度调整后每股收益为0.32美元，比市场普遍预期的0.31美元高出0.01美元，但低于去年同期的0.56美元，主要原因是勘探支出大幅增加，从1450万美元增至8280万美元。产量达到17.42万桶油当量/日，超过了此前17.2万桶油当量的预期，这主要得益于Eagle Ford页岩油田的优异表现和海上作业的稳定运行。同时，原油产量达到8.72万桶/日，也超出预期。营收增长8.9%至7.324亿美元。本季度业绩出现积极转机，自由现金流转正，调整后EBITDAX增长31.9%至4.657亿美元，表明尽管科特迪瓦和越南的勘探成本较高，但公司运营业绩依然强劲。由于勘探成本分摊到下半年，资本支出为 4.65 亿美元，低于此前 5.4 亿美元的预期中值。关键开发里程碑仍按计划进行，其中 Chinook #8 油田预计将于 2026 年下半年开工，日产量目标为 15,000 桶油当量；越南 Lac Da Vang 油田预计将于 2026 年第四季度实现首油；新获批的 Banjo/Cello 油田预计将于 2027 年第四季度实现首油。
Related Articles
Asia
StarHub's Net Attributable Profit Falls 81% in Q1
StarHub's (SGX:CC3) net attributable profit to shareholders plunged 81% in the first quarter of the year to SG$5.9 million from SG$31.8 million a year earlier, according to a Thursday filing with the Singapore Exchange.Revenue declined 6.1% year over year to SG$507.3 million from SG$540.5 million, mainly due to an across-the-board decline in services revenue.
$SGX:CC3
Asia
Meesho Narrows Consolidated Loss in Fiscal Q4
Meesho (NSE:MEESHO, BOM:544632) narrowed its consolidated attributable loss to 1.66 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 13.9 billion rupees a year ago.Loss per share contracted to 0.36 rupees from a loss per share of 3.39 rupees a year earlier, the online marketplace said in a filing to the Indian stock exchanges on Wednesday. The loss per share was lower than the 0.73 rupees estimated by the analysts polled by Visible Alpha.Revenue from operations in fiscal Q4 increased to 35.3 billion rupees from 24.0 billion rupees a year ago. This is a tad higher than Visible Alpha's estimate of 35.2 billion rupees a year ago.
$BOM:544632$NSE:MEESHO
Asia
Changchun High-Tech Gets Regulatory Nod for Gouty Arthritis Drug
Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory approval to manufacture and market its fuxinqibai monoclonal antibody injection.The drug is indicated for acute gouty arthritis attacks in adults poorly responsive to standard therapies, according to a Thursday filing with the Shenzhen bourse.
$SHE:000661